Randomised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention. Issue 10 (10th May 2016)
- Record Type:
- Journal Article
- Title:
- Randomised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention. Issue 10 (10th May 2016)
- Main Title:
- Randomised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention
- Authors:
- Gonçalves, Andre Leite
Martini Ferreira, Adriana
Ribeiro, Reinaldo Teixeira
Zukerman, Eliova
Cipolla-Neto, José
Peres, Mario Fernando Prieto - Abstract:
- Abstract : Introduction: Melatonin has been studied in headache disorders. Amitriptyline is efficacious for migraine prevention, but its unfavourable side effect profile limits its use. Methods: A randomised, double-blind, placebo-controlled study was carried out. Men and women, aged 18–65 years, with migraine with or without aura, experiencing 2–8 attacks per month, were enrolled. After a 4-week baseline phase, 196 participants were randomised to placebo, amitriptyline 25 mg or melatonin 3 mg, and 178 took a study medication and were followed for 3 months (12 weeks). The primary outcome was the number of migraine headache days per month at baseline versus last month. Secondary end points were responder rate, migraine intensity, duration and analgesic use. Tolerability was also compared between groups. Results: Mean headache frequency reduction was 2.7 migraine headache days in the melatonin group, 2.2 for amitriptyline and 1.1 for placebo. Melatonin significantly reduced headache frequency compared with placebo (p=0.009), but not to amitriptyline (p=0.19). Melatonin was superior to amitriptyline in the percentage of patients with a greater than 50% reduction in migraine frequency. Melatonin was better tolerated than amitriptyline. Weight loss was found in the melatonin group, a slight weight gain in placebo and significantly for amitriptyline users. Conclusions: Melatonin 3 mg is better than placebo for migraine prevention, more tolerable than amitriptyline and as effectiveAbstract : Introduction: Melatonin has been studied in headache disorders. Amitriptyline is efficacious for migraine prevention, but its unfavourable side effect profile limits its use. Methods: A randomised, double-blind, placebo-controlled study was carried out. Men and women, aged 18–65 years, with migraine with or without aura, experiencing 2–8 attacks per month, were enrolled. After a 4-week baseline phase, 196 participants were randomised to placebo, amitriptyline 25 mg or melatonin 3 mg, and 178 took a study medication and were followed for 3 months (12 weeks). The primary outcome was the number of migraine headache days per month at baseline versus last month. Secondary end points were responder rate, migraine intensity, duration and analgesic use. Tolerability was also compared between groups. Results: Mean headache frequency reduction was 2.7 migraine headache days in the melatonin group, 2.2 for amitriptyline and 1.1 for placebo. Melatonin significantly reduced headache frequency compared with placebo (p=0.009), but not to amitriptyline (p=0.19). Melatonin was superior to amitriptyline in the percentage of patients with a greater than 50% reduction in migraine frequency. Melatonin was better tolerated than amitriptyline. Weight loss was found in the melatonin group, a slight weight gain in placebo and significantly for amitriptyline users. Conclusions: Melatonin 3 mg is better than placebo for migraine prevention, more tolerable than amitriptyline and as effective as amitriptyline 25 mg. … (more)
- Is Part Of:
- Journal of neurology, neurosurgery and psychiatry. Volume 87:Issue 10(2016)
- Journal:
- Journal of neurology, neurosurgery and psychiatry
- Issue:
- Volume 87:Issue 10(2016)
- Issue Display:
- Volume 87, Issue 10 (2016)
- Year:
- 2016
- Volume:
- 87
- Issue:
- 10
- Issue Sort Value:
- 2016-0087-0010-0000
- Page Start:
- 1127
- Page End:
- 1132
- Publication Date:
- 2016-05-10
- Subjects:
- MIGRAINE
Neurology -- Periodicals
Nervous system -- Surgery -- Periodicals
Psychiatry -- Periodicals
616.8 - Journal URLs:
- http://jnnp.bmjjournals.com/ ↗
http://www.pubmedcentral.nih.gov/tocrender.fcgi?action=archive&journal=192 ↗
http://www.bmj.com/archive ↗ - DOI:
- 10.1136/jnnp-2016-313458 ↗
- Languages:
- English
- ISSNs:
- 0022-3050
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 19186.xml